Vitanova Biomedical

Vitanova Biomedical is a private, preclinical-stage biotech founded in 2018 and based in San Antonio, Texas. The company is pioneering a 'veterinary-first' development strategy for its Light-Activated Intracellular Acidosis (LAIA) platform, initially targeting canine melanoma, hemangiosarcoma, and osteosarcoma. By securing FDA Center for Veterinary Medicine approval first, Vitanova aims to validate its technology, establish a regulatory blueprint, and generate early data to support future translation into human cancer therapies. The platform combines tumor-targeted nanoparticles with non-thermal laser activation to induce cancer cell death via intracellular acidosis.

Light-Activated Intracellular Acidosis (LAIA): A combination therapy using antibody-conjugated, intratumorally injected nanoparticles that are activated by a specific wavelength of laser light to induce rapid intracellular acidosis (low pH) selectively in cancer cells, causing cell death without thermal damage to healthy tissue. An AI model is in development to optimize laser parameters for precise tumor coverage.

In veterinary oncology, competition includes existing chemotherapies, radiation, and newer targeted therapies. In the broader human space, Vitanova competes with other photodynamic therapies, localized ablation technologies, and a wide array of targeted and immunotherapies. Its differentiation lies in the specific acidosis mechanism and its unique veterinary-to-human development path.